You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Psoriasis
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Crohns Disease
SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Psoriasis
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Crohns Disease
SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Psoriasis
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Crohns Disease
SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Psoriasis
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Crohns Disease
SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.
600 mg/10 mL Vial: The solution is colourless to slightly yellow and clear to slightly opalescent. The solution may contain a few translucent to white product-related particles.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Psoriasis
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Crohns Disease
SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.
360 mg/2.4 mL pre-filled cartridge: The solution is colourless to yellow and clear to slightly opalescent. The solution may contain a few translucent to white product-related particles.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Psoriasis
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.
Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Crohns Disease
SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.
180 mg/1.2 mL pre-filled cartridge: The solution is colourless to yellow and clear to slightly opalescent. The solution may contain a few translucent to white product-related particles.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
